Wybo Ingrid, Piérard Denis, Verschraegen Inge, Reynders Marijke, Vandoorslaer Kristof, Claeys Geert, Delmée Michel, Glupczynski Youri, Gordts Bart, Ieven Margaretha, Melin Pierrette, Struelens Marc, Verhaegen Jan, Lauwers Sabine
Academisch Ziekenhuis Vrije Universiteit Brussel, 1090 Brussels, Belgium.
J Antimicrob Chemother. 2007 Jan;59(1):132-9. doi: 10.1093/jac/dkl458. Epub 2006 Nov 9.
To collect recent data on the susceptibility of anaerobes and to compare them with results from previous studies.
Four hundred and forty-three anaerobic clinical isolates from various body sites were prospectively collected from October 2003 to February 2005 in nine Belgian hospitals. MICs were determined for nine anti-anaerobic and three recently developed antibiotics.
Most gram-negative bacilli except Fusobacterium spp. were resistant to penicillin. Piperacillin/tazobactam, metronidazole, chloramphenicol, meropenem and amoxicillin/clavulanic acid were very active against all groups, but only 86% of Bacteroides fragilis group strains were susceptible to the latter. Cefoxitin, cefotetan and clindamycin were less active. In particular, only 62%, 52% and 48% of B. fragilis group strains were susceptible, respectively. Clindamycin shows a continuing decrease in activity, as 83% were still susceptible in 1987 and 66% in 1993-94. Anti-anaerobic activity of the new antibiotics is interesting, with MIC50 and MIC90 of 1 and >32 mg/L for moxifloxacin, 2 and 4 mg/L for linezolid and 0.5 and 8 mg/L for tigecycline.
The susceptibility of anaerobic bacteria remains stable in Belgium, except for clindamycin, which shows a continuous decrease in activity. However, for each of the tested antibiotics, at least a few resistant organisms were detected. Consequently, for severe infections involving anaerobic bacteria, it could be advisable to perform microbiological testing instead of relying on known susceptibility profiles. Periodically monitoring background susceptibility remains necessary to guide empirical therapy.
收集厌氧菌药敏的近期数据,并与以往研究结果进行比较。
2003年10月至2005年2月期间,在比利时的9家医院前瞻性收集了443株来自不同身体部位的厌氧临床分离株。测定了9种抗厌氧菌抗生素和3种新开发抗生素的最低抑菌浓度(MIC)。
除梭杆菌属外,大多数革兰氏阴性杆菌对青霉素耐药。哌拉西林/他唑巴坦、甲硝唑、氯霉素、美罗培南和阿莫西林/克拉维酸对所有菌群都有很强的活性,但脆弱拟杆菌群菌株中只有86%对后者敏感。头孢西丁、头孢替坦和克林霉素的活性较低。特别是,脆弱拟杆菌群菌株中分别只有62%、52%和48%敏感。克林霉素的活性持续下降,1987年仍有83%敏感,1993 - 1994年为66%。新抗生素的抗厌氧菌活性令人关注,莫西沙星的MIC50和MIC90分别为1和>32mg/L,利奈唑胺为2和4mg/L,替加环素为0.5和8mg/L。
在比利时,厌氧菌的药敏情况保持稳定,但克林霉素活性持续下降。然而,对于每种测试抗生素,至少检测到了一些耐药菌。因此,对于涉及厌氧菌的严重感染,进行微生物检测而非依赖已知的药敏谱可能更为可取。定期监测背景药敏情况对于指导经验性治疗仍然必要。